EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases

Subashchandrabose Chinnathambi, Nagaraj Rangappa

Advances in Protein Chemistry and Structural Biology · 2025

DOI: 10.1016/bs.apcsb.2025.10.014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Protein Chemistry and Structural Biology, 2025. Verfasst von Subashchandrabose Chinnathambi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore,…. Hauptthemen laut MEDLINE: Proteostasis Deficiencies, Biosimilar Pharmaceuticals, Single-Domain Antibodies, Neurodegenerative Diseases. Die Arbeit nennt 205 Literaturangaben. Gefördert von: National Institutes of Health, National Institute on Aging, National Institute of Mental Health and Neurosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases, such as Alzheimer's disease, and Parkinson's disease, are characterized by progressive neuronal dysfunction and degeneration. These conditions often share pathological hallmarks such as protein misfolding, oxidative stress, neuroinflammation, and mitochondrial dysfunction. This review focuses on key pathological players like Tau and Amyloid-beta in Alzheimer's disease, highlighting their roles in microtubule destabilization, synaptic dysfunction, and neuronal death. The interplay between oxidative stress and these proteinopathies exacerbates neurodegeneration. Recent advances in therapeutic strategies are also explored, particularly the promise of biosimilars, cost-effective alternatives to biologics, targeting pathological hallmarks in neurodegenerative diseases. Biosimilars targeting Tau and Amyloid-beta in Alzheimer's disease, and alpha-synuclein in Parkinson's disease, hold the potential to improve treatment accessibility and reduce economic burdens. However, their development is still in its early stages. This review underscores the urgent need for innovative, affordable, and globally accessible therapeutic solutions to address the rising burden of neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteostasis DeficienciesBiosimilar PharmaceuticalsSingle-Domain AntibodiesNeurodegenerative DiseasesAlzheimer DiseaseParkinson DiseaseHumanstau ProteinsAmyloid beta-PeptidesAnimalsalpha-Synuclein

Stichwörter der Autor:innen

ADAmyloid βBiosimilarsNeurodegenerative diseasesOxidative stressTau

Substanzen

Biosimilar Pharmaceuticalstau ProteinsSingle-Domain AntibodiesAmyloid beta-Peptidesalpha-Synuclein

Autor:innen und Institutionen

  • Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India. Electronic address: subashneuro@nimhans.ac.in.
  • Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India.

Förderung

  • National Institutes of Health
  • National Institute on Aging
  • National Institute of Mental Health and Neurosciences

Zitieren

APA

Chinnathambi, S., & Rangappa, N. (2025). Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases. Advances in Protein Chemistry and Structural Biology. https://doi.org/10.1016/bs.apcsb.2025.10.014

Vancouver

Chinnathambi S, Rangappa N. Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases. Advances in Protein Chemistry and Structural Biology. 2025. doi:10.1016/bs.apcsb.2025.10.014

BibTeX
@article{Chinnathambi2025,
  author = {Chinnathambi, Subashchandrabose and Rangappa, Nagaraj},
  title = {Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases},
  journal = {Advances in Protein Chemistry and Structural Biology},
  year = {2025},
  doi = {10.1016/bs.apcsb.2025.10.014}
}
Kostenlos starten →